Maddie Meyer/Getty Images News Moderna ( NASDAQ: MRNA ) shares traded in the green on Tuesday, making it the seventh consecutive day of gains. Stock closed up 1.90% at $143.
69. MRNA has risen 11.26% in the last 12 months and gained 39% in the last one month.
YTD, the stock is trading above the broader S&P 500 market which rose 11.29% as compared to MRNA’s YTD gain of 41.79%.
Looking at Seeking Alpha's Quant Ratings, this Massachusetts based company has a Hold rating with a score of 3.18 out of 5. When it comes to Wall Street analysis, 10 out of 25 analysts recommend a Hold , 8 rate it as a Strong Buy, 4 rate it as a Buy, 2 rate it as a Strong Sell and 1 rates it as a Sell.
Seeking Alpha analysts have a Hold rating on the company. Moderna announced this month that the U.S.
FDA has pushed back its timeline to complete the review of its marketing application for mRNA-1345, a messenger-RNA-based vaccine against respiratory syncytial virus. According to SA analyst, Biotech Beast, “MRNA has the potential to offset revenue declines from its COVID vaccine business with revenues from other vaccines for infectious diseases, but also vaccines for cancer.” Moderna beat forecasts with its Q1 2024 financials earlier this month, even as the company’s top line declined, driven by the lower demand for its COVID-19 vaccine.
More on Moderna Aggressive Strides Forward For Moderna's Cancer Vaccine Moderna Q1: A Promising Pipeline Is Undervalued Moderna, Inc. (MRNA) Q1 2024 Earnings Call T.